The Effect of Aprepitant Reducing Postoperative Nausea and Vomiting

The Effect of Aprepitant Reducing Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Gastric Sleeve Surgery

The purpose of this study is to assess the efficacy of Aprepitant + standard antiemetic regimen in reducing postoperative nausea and vomiting after laparoscopic gastric sleeve versus placebo + standard antiemetic regimen

After being informed about the study, all patients who provide written informed consent and meet the eligibility requirements will be randomized in a triple-blind manner (participant, evaluator, and investigator) in a 1:1 ratio to Aprepitant (80 or 125 mg) + standard antiemetic regimen (once two hours before surgery) or placebo + standard antiemetic regimen(once two hours before surgery).

The standard antiemetic regimen will be Ondansetron 8 mg + Metoclopramide 10 mg + Dexamethasone 8 mg

Inclusion Criteria:

• 18 to 65 years old.
• Non-smokers.
• Obesity with BMI > 30 kg/m2.
• Undergoing laparoscopic gastric sleeve.

Exclusion Criteria:

• Documented hypersensitivity to any component of the study regimen.
• Current treatment with: Orap (pimozide), Seldane (terfenadine), Hismanal (astemizole) or Propulsid (cisapride).
• Allergy to opioid drugs used in the anesthetic protocol.
• Drug or alcohol abuse.
• Chronic nausea and vomiting.
• Previous bariatric procedures.